Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC
Kristen Neumann, DNP, FNP-C, and Misako Nagasaka, MD, PhD, discuss the importance of patient education on diarrhea as a side effect of EGFR-mutated non-small cell lung cancer treatment, emphasizing dietary considerations and the use of over-the-counter remedies.
EP: 1.Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC
Now Viewing
EP: 2.Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC
EP: 3.Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs
EP: 4.Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC
EP: 5.Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation
EP: 6.Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations
EP: 7.Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC
EP: 8.Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)
EP: 9.EGFR Mutations in Patients With NSCLC
EP: 10.Adverse Effect Management in Non–Small Cell Lung Cancer Treatment
EP: 11.Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC
EP: 12.The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC
EP: 13.Multidisciplinary Care, Approval Updates, and Future Research in NSCLC
EP: 14.Treatment Approaches for Patients With EGFR-Mutant NSCLC
EP: 15.Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC
EP: 16.Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance
EP: 17.Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations
EP: 18.Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations
EP: 19.The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations
EP: 20.Unmet Needs and Future Perspectives in NSCLC Treatment
EP: 21.New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies
Recent Videos
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
